---
title: "China Resources Pharmaceutical Raises RMB2 Billion in Third Tranche of 2026 PRC Bonds"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/290965367.md"
description: "China Resources Pharmaceutical Group announced that its subsidiary completed the public issuance of the third tranche of 2026 corporate bonds, totaling RMB2 billion. The three-year bonds carry a 1.59% annual coupon rate. Net proceeds will fund working capital, repay debt, and support project investments, aiming to enhance liquidity and financial flexibility for the group's pharmaceutical distribution operations."
datetime: "2026-06-26T12:18:44.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/290965367.md)
  - [en](https://longbridge.com/en/news/290965367.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/290965367.md)
generator: "portal-rs"
---

# China Resources Pharmaceutical Raises RMB2 Billion in Third Tranche of 2026 PRC Bonds

China Resources Pharmaceutical Group Ltd. ( (HK:3320) ) has shared an update.

China Resources Pharmaceutical Group Limited has announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group, has completed the public issuance of the third tranche of its 2026 corporate bonds in mainland China. The new bonds total RMB2 billion, carry a three-year term and a coupon rate of 1.59% per year, adding to earlier tranches issued in 2026.

The company plans to use the net proceeds to fund production-related expenditures, including working capital replenishment, repayment of interest-bearing debt and project investments, in line with applicable laws and regulations. The fundraising move is expected to bolster the group’s liquidity and financial flexibility, supporting ongoing operations in the pharmaceutical distribution sector while signaling continued access to onshore bond markets for its commercial platform.

**More about China Resources Pharmaceutical Group Ltd.**

China Resources Pharmaceutical Group Limited is a Hong Kong–incorporated pharmaceutical company with operations in mainland China, focusing on pharmaceutical distribution and related commercial services through subsidiaries such as China Resources Pharmaceutical Commercial Group Company Limited. The group serves the broader healthcare market, supporting production, working capital needs and project investments across China’s pharmaceutical supply chain.

**Average Trading Volume:** 17,123,539

**Technical Sentiment Signal:** Sell

**Current Market Cap:** HK$27.83B

Learn more about 3320 stock on TipRanks’ Stock Analysis page.

### Related Stocks

- [03320.HK](https://longbridge.com/en/quote/03320.HK.md)

## Related News & Research

- [China Resources Pharmaceutical Completes RMB1.4 Billion Second Tranche of 2026 Bonds in China](https://longbridge.com/en/news/284352645.md)
- [What smart investors are saying about a 2007-era warning flashing in the bond market](https://longbridge.com/en/news/296244920.md)
- [Analysis - from kangaroos to dim sum, foreign borrowers rush into Asia-Pacific bond markets](https://longbridge.com/en/news/296050739.md)
- [The bond market explained and why it matters](https://longbridge.com/en/news/296385967.md)
- [REG - Nationwide B.S. Nationwide BS- 34VG - Notification Admission to trading of Covered Bonds](https://longbridge.com/en/news/296631029.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**